Back to Journals » Cancer Management and Research » Volume 11

An integrated prediction model of recurrence in endometrial endometrioid cancers

Authors Miller MD, Salinas EA, Newtson AM, Sharma D, Keeney ME, Warrier A, Smith BJ, Bender DP, Goodheart MJ, Thiel KW, Devor EJ, Leslie KK, Gonzalez-Bosquet J

Received 23 January 2019

Accepted for publication 22 March 2019

Published 6 June 2019 Volume 2019:11 Pages 5301—5315

DOI https://doi.org/10.2147/CMAR.S202628

Checked for plagiarism Yes

Review by Single-blind

Peer reviewers approved by Dr Cristina Weinberg

Peer reviewer comments 2

Editor who approved publication: Dr Beicheng Sun


Marina D Miller,1 Erin A Salinas,1 Andreea M Newtson,1 Deepti Sharma,1 Matthew E Keeney,2 Akshaya Warrier,1 Brian J Smith,3 David P Bender,1,4 Michael J Goodheart,1,4 Kristina W Thiel,1 Eric J Devor,1,4 Kimberly K Leslie,1,4 Jesus Gonzalez-Bosquet1,4

1Department of Obstetrics and Gynecology, University of Iowa Carver College of Medicine, Iowa City, IA, USA; 2Department of Pathology, University of Iowa Carver College of Medicine, Iowa City, IA, USA; 3Department of Biostatistics, University of Iowa College of Public Health, Iowa City, IA, USA; 4Holden Comprehensive Cancer Center, University of Iowa Carver College of Medicine, Iowa City, IA, USA

Objectives: Endometrial cancer incidence and mortality are rising in the US. Disease recurrence has been shown to have a significant impact on mortality. However, to date, there are no accurate and validated prediction models that would discriminate which individual patients are likely to recur. Reliably predicting recurrence would be of benefit for treatment decisions following surgery. We present an integrated model constructed with comprehensive clinical, pathological and molecular features designed to discriminate risk of recurrence for patients with endometrioid endometrial adenocarcinoma.
Subjects and methods: A cohort of endometrioid endometrial cancer patients treated at our institution was assembled. Clinical characteristics were extracted from patient charts. Primary tumors from these patients were obtained and total tissue RNA extracted for RNA sequencing. A prediction model was designed containing both clinical characteristics and molecular profiling of the tumors. The same analysis was carried out with data derived from The Cancer Genome Atlas for replication and external validation.
Results: Prediction models derived from our institutional data predicted recurrence with high accuracy as evidenced by areas under the curve approaching 1. Similar trends were observed in the analysis of TCGA data. Further, a scoring system for risk of recurrence was devised that showed specificities as high as 81% and negative predictive value as high as 90%. Lastly, we identify specific molecular characteristics of patient tumors that may contribute to the process of disease recurrence.
Conclusion: By constructing a comprehensive model, we are able to reliably predict recurrence in endometrioid endometrial cancer. We devised a clinically useful scoring system and thresholds to discriminate risk of recurrence. Finally, the data presented here open a window to understanding the mechanisms of recurrence in endometrial cancer.

Keywords: endometrial cancer, recurrence risk, prediction model

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]